Cortisol and Phosphate Homeostasis: Cushing’s Syndrome Is Associated With Reversible Hypophosphatemia

by Ariadne Bosman, Annewieke W. van den Beld, Annewieke W. van den Beld, Richard A. Feelders, M. Carola Zillikens
Published 2021-09-01

The role of mTOR pathway as target for treatment in adrenocortical cancer

by Maria Cristina De Martino, Richard A Feelders, Claudia Pivonello, Chiara Simeoli, Fortuna Papa, Annamaria Colao, Rosario Pivonello, Leo J Hofland
Published 2019-09-01

How to Differentiate Benign from Malignant Adrenocortical Tumors?

by Charlotte L. Viëtor, Sara G. Creemers, Folkert J. van Kemenade, Tessa M. van Ginhoven, Leo J. Hofland, Richard A. Feelders
Published 2021-08-01

Patient-specific workup of adrenal incidentalomas

by Romy R. de Haan, Johannes B.R. Visser, Ewoud Pons, Richard A. Feelders, Uzay Kaymak, M.G. Myriam Hunink, Jacob J. Visser
Published 2017-01-01

Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours

by Anela Blažević, Tessa Brabander, Wouter T. Zandee, Johannes Hofland, Gaston J. H. Franssen, Marie-Louise F. van Velthuysen, Richard A. Feelders, Wouter W. De Herder
Published 2021-01-01

Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?

by Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Richard A Feelders, Patric J D Delhanty, Wouter W de Herder, Piet Kramer
Published 2016-07-01

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study

by Rosario Pivonello, Atanaska Elenkova, Maria Fleseriu, Richard A. Feelders, Przemyslaw Witek, Yona Greenman, Eliza B. Geer, Paola Perotti, Leonard Saiegh, Fredric Cohen, Giorgio Arnaldi
Published 2021-04-01

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

by Rosario Pivonello, Irina Bancos, Richard A. Feelders, Atil Y. Kargi, Janice M. Kerr, Murray B. Gordon, Cary N. Mariash, Massimo Terzolo, Noel Ellison, Andreas G. Moraitis
Published 2021-07-01

Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.

by Johannes Hofland, Jacobie Steenbergen, Jacoba M Voorsluijs, Michael M P J Verbiest, Ronald R de Krijger, Leo J Hofland, Wouter W de Herder, Andre G Uitterlinden, Richard A Feelders, Frank H de Jong
Published 2014-01-01

Development and Internal Validation of a Multivariable Prediction Model for Adrenocortical-Carcinoma-Specific Mortality

by Madeleine H. T. Ettaieb, Sander M. J. van Kuijk, Annelies de Wit-Pastoors, Richard A. Feelders, Eleonora P. M. Corssmit, Elisabeth M. W. Eekhoff, Paul van der Valk, Henri J. L. M. Timmers, Michiel N. Kerstens, Heinz-Josef Klümpen, van Rachel S. Leeuwaarde, Bas Havekes, Harm R. Haak
Published 2020-09-01

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

by Ingrid M. Zandbergen, Amir H. Zamanipoor Najafabadi, Iris C. M. Pelsma, M. Elske van den Akker-van Marle, Peter H. L. T. Bisschop, H. D. Jeroen Boogaarts, Arianne C. van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M. Dekkers, Madeleine L. Drent, Richard A. Feelders, Johan P. de Graaf, J. Hoogmoed, Kitty K. Kapiteijn, Melanie M. van der Klauw, Willy-Anne C. M. Nieuwlaat, Alberto M. Pereira, Aline M. E. Stades, Annenienke C. van de Ven, Iris M. M. J. Wakelkamp, Wouter R. van Furth, Nienke R. Biermasz, on behalf of the Dutch Prolactinoma Study Group
Published 2021-09-01